Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226829 | 0.92 | SLC22A12 (0.38) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10226533 | 0.91 | EGLN1 (0.36) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL15925189 | 0.91 | LMNA (0.35) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10226531 | 0.91 | LMNA (0.35) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10227771 | 0.90 | SLC22A12 (0.36) | SLC22A12EGLN1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10226532 | 0.90 | ALDH1A1 (0.36) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10226530 | 0.89 | EGLN1 (0.35) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10228700 | 0.88 | SLC22A12 (0.51) | SLC22A12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL10228272 | 0.84 | SLC22A12 (0.52) | SLC22A12LMNAGAAHPGDSMN1; SMN2 | |
| SCHEMBL10226528 | 0.83 | TP53 (0.35) | SLC22A12LMNAGAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | ARDEA BIOSCIENCES INC. | 2019-05-16 | — | — | US | disclosed |
| US-10183012-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-2217577-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8546437-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8357713-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8283369-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES. INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084483-B2 | Compounds and compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164222-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-20090197825-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-10183012-B2 | Compounds and compositions and methods of use | XDH, PON1, OAT | SLC22A12 815/4885LMNA 258/4885GAA 155/4885 |
| US-20110268801-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-20160221970-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-20110293719-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
| US-20190142805-A1 | Novel Compounds and Compositions and Methods of Use | XDH, PON1, GLS | SLC22A12 1122/4885LMNA 503/4885GAA 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.